TABLE 2.
Cardiovascular disease risk factors stratified by age among the female Nunavik (Quebec) Inuit population
|
Age, years |
P* | MetS | Framingham risk category | |||||
|---|---|---|---|---|---|---|---|---|
| 20–39 (n=27) | 40–49 (n=278) | 50–59 (n=91) | 60–69 (n=56) | ≥70 (n=46) | ||||
| Body mass index, kg/m2 | 24.6 (0.8) | 27.4 (0.3) | 27.4 (0.6) | 28.7 (0.8) | 31.4 (1.0) | <0.0001 | 9.9 (1.3) | Multiple risk factors and 10-year risk ≤20%: 0.5% |
| Body fat, % | 26.0 (1.5) | 31.3 (0.5) | 31.1 (1.0) | 31.1 (1.0) | 33.7 (1.1) | <0.0001 | ||
| Waist circumference, cm | 83.3 (2.2 | 89.4 (0.7) | 91.0 (1.4) | 96.1 (1.9) | 103.0 (202) | <0.0001 | ||
| Systolic BP, mmHg | 109 (1) | 111 (1) | 114 (1) | 122 (2) | 137 (3) | <0.0001 | ||
| Diastolic BP, mmHg | 72 (0) | 68 (1) | 72 (1) | 73 (1) | 74 (1) | <0.0001 | ||
| TC, mmol/L | 4.3 (0.2) | 4.9 (0.1) | 5.3 (0.1) | 5.7 (0.1) | 5.5 (0.1) | <0.0001 | ||
| TC/HDL-C ratio† | 2.7 (0.01) | 3.0 (0.1) | 3.0 (0.1) | 3.0 (0.1) | 3.0 (0.1) | <0.0001 | ||
| HDL-C, mmol/L | 1.6 (0.1) | 1.7 (0.02) | 1.8 (0.05) | 2.0 (0.1) | 1.9 (0.1) | <0.0001 |
0 to 1 risk factor: 99.5% |
|
| LDL-C, mmol/L | 2.2 (0.1) | 2.7 (0.01) | 2.8 (0.1) | 3.0 (0.1) | 2.9 (0.1) | <0.0001 | ||
| Triglycerides†, mmol/L | 0.9 (0.01) | 1.0 (0.03) | 1.1 (0.04) | 1.1 (0.1) | 1.2 (0.1) | 0.04 | ||
| HOMA-IR† (n=216) | 1.2 (0.1) | 1.4 (0.1) | 1.3 (0.1) | 1.6 (0.1) | 2.2 (0.2) | 0.003 | ||
| Fasting glucose†, mmol/L | 4.0 (0.1) | 4.2 (0.1) | 4.5 (0.1) | 5.0 (0.2) | 5.1 (0.2) | <0.0001 | ||
| Fasting insulin†, pmol/L | 48.8 (4.4) | 51.0 (1.6) | 46.0 (2.5) | 52.0 (3.5) | 67.3 (6.1) | 0.16 | ||
| Smoking (yes), % | 100 (–) | 86.4 (2.0) | 85.2 (3.6) | 60.0 (6.5) | 39.3 (7.4) | <0.0001 | ||
| Sedentary lifestyle, % | 50.8 (10.19) | 71.0 (3.0) | 53.3 (5.2) | 56.0 (7.2) | 71.3 (7.0) | 0.473 | ||
Data presented as arithmetic mean (standard error) unless otherwise indicated.
*
P values correspond to a linear trend across age categories;
†
Data presented as geometric mean (standard error). BP Blood pressure; HDL-C High-density lipoprotein cholesterol; HOMA-IR Homeostasis model assessment – insulin resistance; LDL-C Low-density lipoprotein cholesterol; MetS Metabolic syndrome; TC Total cholesterol